Trial Profile
A Phase II Single-arm Trial of Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Apr 2022 Results assessing combination of bevacizumab plus atezolizumab for metastatic NSCLC, published in the Journal of Thoracic Oncology
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer
- 13 Aug 2018 New trial record